ilaprazole has been researched along with clavulanic acid in 1 studies
| Studies (ilaprazole) | Trials (ilaprazole) | Recent Studies (post-2010) (ilaprazole) | Studies (clavulanic acid) | Trials (clavulanic acid) | Recent Studies (post-2010) (clavulanic acid) |
|---|---|---|---|---|---|
| 53 | 24 | 42 | 1,801 | 212 | 424 |
| Protein | Taxonomy | ilaprazole (IC50) | clavulanic acid (IC50) |
|---|---|---|---|
| Beta-lactamase | Klebsiella pneumoniae | 1.72 | |
| Beta-lactamase | Escherichia coli | 0.07 | |
| Beta-lactamase | Citrobacter gillenii | 0.009 | |
| Beta-lactamase | Shouchella clausii | 0.085 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Staphylococcus aureus | 0.08 | |
| Beta-lactamase | Escherichia coli K-12 | 0.015 | |
| Beta-lactamase SHV-1 | Escherichia coli | 0.028 | |
| Beta-lactamase SHV-1 | Klebsiella pneumoniae | 0.17 | |
| Beta-lactamase OXA-1 | Escherichia coli | 3.2 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 0.17 | |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | 0.8 | |
| Beta-lactamase TEM | Escherichia coli | 0.0933 | |
| Beta-lactamase | Salmonella enterica subsp. enterica serovar Westhampton | 0.01 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.1 | |
| Beta-lactamase | Klebsiella pneumoniae | 0.02 | |
| Class D beta-lactamase | Brachyspira pilosicoli | 2 | |
| Beta-lactamase | Pseudomonas luteola | 0.036 | |
| Beta-lactamase | Escherichia coli | 8.6 | |
| Beta-lactamase | Escherichia coli | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, MZ; Cong, YY; Huang, XP; Huang, YY; Liao, XM; Nong, GH; Wei, JQ; Wu, BH | 1 |
1 trial(s) available for ilaprazole and clavulanic acid
| Article | Year |
|---|---|
Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; China; Chronic Disease; Clavulanic Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2015 |